Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blood Products Start-Ups

This article was originally published in Start Up

Executive Summary

In blood products, the marketplace hurdles are as high as the technological ones. But that's not stopping new players from trying.

You may also be interested in...



Another Layer of Safety for the Blood Supply

Cerus has received European regulatory approval for a pathogen inactivation system that its president describes as the first "prospective" approach to blood safety. Cerus and marketing partner Baxter plan to launch the device in Europe by year-end. The device inactivates all pathogens in platelets, in contrast to existing blood screening tests, which look for specific infectious agents and don't address the risk of emerging pathogens. The partners have a long series of hurdles to overcome, not least of which is the difficulty of convincing potential buyers to pay more for a technology that addresses theoretical risk.

Transfusion Technologies Corp.

Transfusion Technologies is streamlining blood collection and recovery through automation.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel